Aclarion, Inc. (Nasdaq: ACON) has entered into a commercial agreement with the prestigious London Clinic, a renowned independent hospital in London's medical district. This collaboration allows Aclarion to leverage the Clinic's advanced facilities and commitment to technological advancements in providing exceptional medical care. 

Aclarion's initial focus is on addressing the chronic low back pain market with their innovative SaaS platform called Nociscan, which enables physicians to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, supported by evidence.

$ACON is trading at $1.43 (+132.10%) in pre-market, following the announcement.

HeartBeam, Inc. (Nasdaq: BEAT) has forged a Strategic Alliance Agreement (SAA) with Samsung to explore collaboration opportunities in the assessment and monitoring of cardiac symptoms. 

Leveraging HeartBeam's expertise and patented technology, this alliance aims to identify new avenues for advancements in cardiac care. The agreement signifies the recognition of HeartBeam's capabilities and marks a significant step forward in enhancing the diagnosis and management of heart-related conditions.

In pre-market, $BEAT is trading at $2.89, reflecting a positive change of $0.71 or 32.57%.

Kenvue Inc. (NYSE: KVUE) has received initiation coverage from multiple financial institutions, each providing their assessment and price target for the company. 

BofA Securities has initiated coverage with a Buy rating and a price target of $30, Exane BNP Paribas with a Neutral rating and a price target of $28, Citigroup with a Neutral rating and a price target of $28, Deutsche Bank with a Hold rating and a price target of $27, JP Morgan with an Overweight rating and a price target of $29, RBC Capital Markets with an Outperform rating and a price target of $29, and Goldman Sachs with a Neutral rating and a price target of $29.

As of pre-market, $KVUE is trading at $26.55, showing a slight increase of $0.25 (0.95%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)